Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
wet AMD
Pharma
EyePoint reeling for stability after another AMD ph. 3 flop
In the wake of the phase 3 flop, EyePoint will reduce its workforce by 53% and cut its phase 3 wet AMD trials short.
Donavyn Coffey
Oct 19, 2026 11:32am
Ocular's ophthalmologic version of Inlyta bests Eylea in ph. 3
Feb 17, 2026 12:15pm
Roche eyes busy 2026 despite Vabysmo miss, Tecentriq flop
Jan 29, 2026 11:23am
Ocular hires Eylea launch architect to challenge Regeneron
Jan 23, 2026 10:00am
Regeneron wins 2 Eylea nods, ramping up competition with Roche
Nov 20, 2025 11:53am
Ocular Therapeutix sharpens focus with retina-centric rebrand
Jun 27, 2025 10:05am
